Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast

Marmor, Schelomo; Hui, Jane Yuet Ching; Huang, Jing; Kizy, Scott; Beckwith, Heather; Blaes, Anne; Rueth, Natasha M.; Tuttle, Todd M.

doi:10.1002/cncr.30699

Cited by 59 publications

(58 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with these features, ILC patients have a relatively favorable 5-year survival rate. However, these tumors show local recurrence, exhibit diminished response to hormone and chemotherapy compared with invasive ductal carcinoma (IDC) ( Metzger Filho et al, 2015 ; Marmor et al, 2017 ), and can recur as lethal tumors many years after treatment ( Korhonen et al, 2013 ; Pestalozzi et al, 2008 ; Colleoni et al, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast

Adams

Hollern

et al. 2018

Cell Reports

View full text Add to dashboard Cite

SUMMARYCDH1 and PIK3CA are the two most frequently mutated genes in invasive lobular carcinoma (ILC) of the breast. Transcription profiling has identified molecular subtypes for ILC, one of which, immune-related (IR), is associated with gene expression linked to lymphocyte and macrophage infiltration. Here, we report that deletion of Cdh1, together with activation of Pik3ca in mammary epithelium of genetically modified mice, leads to formation of IR-ILC-like tumors with immune cell infiltration, as well as gene expression linked to T-regulatory (Treg) cell signaling and activation of targetable immune checkpoint pathways. Interestingly, these tumors show enhanced Rac1-and Yap-dependent transcription and signaling, as well as sensitivity to PI3K, Rac1, and Yap inhibitors in culture. Finally, high-dimensional immunophenotyping in control mouse mammary gland and IR-ILC tumors by mass cytometry shows dramatic alterations in myeloid and lymphoid populations associated with immune suppression and exhaustion, highlighting the potential for therapeutic intervention via immune checkpoint regulators.

show abstract

Section: Introductionmentioning

confidence: 99%

Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast

Adams

Hollern

et al. 2018

Cell Reports

View full text Add to dashboard Cite

show abstract

“…Analyzing the data from the Netherlands Cancer Registry, for patients with early-stage (pathologically assessed T1 and T2) cancers, patients with ILCs were less likely to undergo breast conserving surgery (43% vs. 54%) than those with ductal cancers 15 . Specific to lobular cancers, two large independent studies using data from the Netherlands Cancer Registry 16 and from the California Cancer Registry 17 , have shown that the combination of adjuvant chemotherapy and adjuvant hormonal therapy did not improve 10-year survival rates over adjuvant hormonal therapy alone.…”

Section: Introductionmentioning

confidence: 99%

Unifocal Invasive Lobular Carcinoma: Tumor Size Concordance Between Preoperative Ultrasound Imaging and Postoperative Pathology

Vijayaraghavan

Vedantham

Santos-Nunez

et al. 2018

Clinical Breast Cancer

View full text Add to dashboard Cite

show abstract

“…They concluded that adjuvant chemotherapy did not confer an additional benefit in patients with lobular cancer . In addition, a more recent study by Marmor et al addressed the impact of adjuvant chemotherapy in the survival of patients with invasive lobular vs invasive ductal cancer within a California data registry. In this study, likewise, adjuvant chemotherapy did not improve outcomes in 4638 patients with ER+ stage I/II invasive lobular cancer.…”

Section: Discussionmentioning

confidence: 99%

The impact of chemotherapy sequence on survival in node‐positive invasive lobular carcinoma

Tamirisa

Williamson

Thomas

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives We sought to evaluate the impact of chemotherapy sequence on survival by comparing node‐positive invasive lobular carcinoma (ILC) patients who received neoadjuvant (NACT) and adjuvant (ACT) chemotherapy. Methods cT1‐4c, cN1‐3 ILC patients in the National Cancer Data Base (2004‐2013) who underwent surgery and chemotherapy were divided into NACT and ACT cohorts. Kaplan‐Meier curves and Cox proportional hazards modeling were used to estimate unadjusted and adjusted overall survival (OS), respectively. Results Five thousand five hundred fifty‐one (35.6%) of 15 573 ILC patients treated with chemotherapy received NACT. NACT patients had similar rates of pT3/4 disease (26.6% vs 26.2%), nodal involvement (median 3 vs 4), and number of lymph nodes examined (median 13 vs 14) but higher rates of mastectomy (81.8% vs 74.5%, P < 0.001) vs ACT patients. 3.4% of NACT patients experienced pathologic complete response (pCR). Unadjusted 10‐year OS was worse for NACT vs ACT patients (65.1% vs 54.4%, log‐rank P < 0.001). After adjustment for known covariates, NACT continued to be associated with worse OS (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.25‐1.52). Conclusions In node‐positive ILC, NACT yielded low rates of pCR, was not associated with lower rates of mastectomy or less extensive axillary surgery, and was associated with worse survival vs ACT, suggesting limited benefit for these patients.

show abstract

Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast

Cited by 59 publications

References 22 publications

Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast

Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast

Unifocal Invasive Lobular Carcinoma: Tumor Size Concordance Between Preoperative Ultrasound Imaging and Postoperative Pathology

The impact of chemotherapy sequence on survival in node‐positive invasive lobular carcinoma

Contact Info

Product

Resources

About